This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutUnmet NeedCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsMode of ActionVideoCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsPatient ProfilesProfiles of Patients With CAPIdentify ZINFORO® Patient With CAPProfiles of Patients With cSSTIIdentify ZINFORO® Patient With cSSTIDosingRecommended Dosing ScheduleSimple DosingRenal AdjustmentEfficacyCommunity-acquired PneumoniaClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesComplicated Skin & Soft Tissue InfectionsClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesSafetySafetyKey safety featuresLow Incidence of Discontinuation in CAPLow Incidence of Discontinuation in cSSTIClinical & Scientific Data Clinical & Scientific Data Efficacy in the Treatment of CAPClinical Cure Rates Against Relevant PathogensClinical Cure Rates Across Patient SubgroupsDemonstrated Superiority to CeftriaxoneEarly Clinical ResponseReal-world Efficacy in Elderly PatientsConsistent Clinical Cure Rates in cSSTIClinical Cure Rates in Common Causative PathogensClinical Cure Rates in Patients With ComorbiditiesEarly Clinical EfficacyReal-life Efficacy in Clinical PracticeSupport & ResourcesSupport & ResourcesClinical updatesPrescribing InformationVideosWebinarsExplore Materials


Community-acquired Pneumonia

ZINFORO®: Bactericidal activity against resistant isolates with high binding affinity in Streptococcus pneumoniae1-3,*
 


The available clinical data cannot substantiate efficacy against penicillin-resistant strains of S. pneumoniae. Caution is advised when treating such patients. ZINFORO® is not indicated for MRSA in CAP – the comparator in the clinical studies, ceftriaxone, is not active against MRSA.5

How does ZINFORO® exert bactericidal activity?

ZINFORO® exerts potent bactericidal activity in cSSTI against resistant isolates with high binding affinity to mutated beta-lactam-binding proteins.1-4,6,7

It achieves bactericidal activity in CAP against resistant isolates with high binding affinity in S. pneumoniae.1-3

ZINFORO® (Ceftaroline fosamil) PK/PD

ZINFORO® (ceftaroline fosamil) has relatively low protein binding affinity (<20%) and would be predicted to attain rapid penetration to the primary infection site.3


ZINFORO® (ceftaroline fosamil) penetrates the bronchial ELF of healthy subjects, with a penetration relative to that of plasma of 23%.8


At a dose of 600 mg every 12 hours and an MIC of 1 mg/L: 

  • A total of 98.1% of patients would be expected to achieve a target-free drug concentration levels above the MIC in plasma; for 600 mg q8h, the proportion would be 100%8
  • A total of 81.7% of patients would be expected to achieve a target MIC in ELF8

Pathogen coverage

ZINFORO® is a fifth-generation cephalosporin with coverage against key pathogens in CAP and cSSTI, including Staphylococcus aureus and S. pneumoniae.1,5

ZINFORO® has demonstrated clinical efficacy against the following pathogens in cSSTI5:

ZINFORO® has demonstrated clinical efficacy against the following pathogens in CAP5:

   



*Recommended for patients without risk factors for MRSA or Pseudomonas aeruginosa.9

ATS, American Thoracic Society; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; ELF, epithelial lining fluid; IDSA, Infectious Diseases Society of America; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PBP2x, penicillin-binding protein 2x; PBP, penicillin-binding protein; PD, pharmacodynamics; PK, pharmacokinetics; q8h, every 8 hours; q12h, every 12 hours.
 

References:

Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(suppl 3):iii11-iii18.Garrison MW, Kawamura NM, Wen MM. Ceftaroline fosamil: a new cephalosporin active against resistant gram-positive organisms including MRSA. Expert Rev Anti Infect Ther. 2012;10(suppl 10):1087-1103.Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? J Antimicrob Chemother. 2011;66(suppl 3):iii61-iii67.Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65(suppl 4):713-716.Zinforo. Local product document. Pfizer; 2021. Version LPDZIN072021.Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(suppl 5):2541-2546.Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem. 2003;11(suppl 11):2427-2437.
 
Riccobene TA, Pushkin R, Jandourek A, Knebel W, Khariton T. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects. Antimicrob Agents Chemother. 2016;60(suppl 10):5849-5857.
 
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(suppl 7):e45-e67.


​​​​​Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
​​​​​​​
PP-ZFO-IND-0417 June 2022
Mode of Action

Example

Example

Dosing

Simple dosing with a flexible infusion time

Learn moreLoading
Efficacy

Proven clinical efficacy in patients with
CAP and cSSTI

 Review efficacy profile


Safety

Safety profile consistent with other cephalosporins

 Review safety profile


Clinical & Scientific Data

​​​​ZINFORO® in the treatment of CAP and cSSTI​​​​​​

 Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ZFO-IND-0417

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023
Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023